BiotechTube
SAB BIO

SAB BIO

San Diego, United States· Est.
sab.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23M

Overview

SAB BIO is a private, pre-revenue biotech founded in 2018, advancing a novel therapeutic approach for Type 1 Diabetes. The company's pipeline is centered on SAB-142, a disease-modifying therapy intended to delay disease progression by modulating the autoimmune attack on pancreatic beta cells. Operating in the high-need autoimmune and diabetes space, SAB BIO represents an early-stage venture with a focused scientific strategy aimed at altering the course of T1D. Its progress is guided by an established leadership and clinical advisory board.

Type 1 DiabetesAutoimmune Diseases

Technology Platform

Antibody-based biologics platform targeting immune modulation to preserve pancreatic beta cell function in autoimmune disease.

Funding History

2
Total raised:$23M
Series A$20M
Seed$3M

Opportunities

The global Type 1 Diabetes market represents a multi-billion dollar opportunity with a profound unmet need for disease-modifying therapies.
Success with SAB-142 could establish a new treatment paradigm and provide a platform expandable to other autoimmune indications.

Risk Factors

High clinical development risk as a single-asset company; potential for SAB-142 to lack efficacy or safety in human trials.
Financial risk is significant, dependent on raising capital in a challenging biotech funding environment.

Competitive Landscape

Competitive with other biopharma companies developing immune-modulating and beta-cell preserving therapies for T1D, including antigen-specific therapies and other biologics. Faces competition from both large pharma and nimble biotech ventures.

More companies in Biologics / Biosimilars →More companies in United States →